Suppr超能文献

拟钙剂对透析患者长期预后的影响:文献综述与贝叶斯荟萃分析

Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis.

作者信息

Lozano-Ortega Greta, Waser Nathalie, Bensink Mark E, Goring Sarah, Bennett Heather, Block Geoffrey A, Chertow Glenn M, Trotman Marie-Louise, Cooper Kerry, Levy Adrian R, Belozeroff Vasily

机构信息

ICON plc, Epidemiology, Vancouver, BC V6B 1P1, Canada.

Departments of Global Health Economics (MB, VB), Biostatistics (MLT), and Global Medical (KC), Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 9132, USA.

出版信息

J Comp Eff Res. 2018 Jul;7(7):693-707. doi: 10.2217/cer-2018-0015. Epub 2018 May 15.

Abstract

AIM

Randomized controlled trials (RCTs) with clinical outcomes are considered the gold standard for regulatory approval. However, by design they are only able to answer a small number of clinical questions. Other high-quality studies are required for clinical decision-making. The EVOLVE was the largest RCT, evaluating the effects of cinacalcet on clinical outcomes among adult patients receiving maintenance dialysis suffering from secondary hyperparathyroidism. While the EVOLVE trial did not reach its primary end point, imbalance in subjects' age at randomization and discontinuation rates are two of the reasons that the lack of mortality benefit is in question. We undertook a systematic literature review and Bayesian meta-analysis combining randomized and observational studies on the estimated effects of the oral calcimimetic cinacalcet on clinical outcomes including all-cause mortality, cardiovascular-related mortality, hospitalization for cardiovascular events, fracture and parathyroidectomy among patients on maintenance dialysis.

METHODS

Data sources included MEDLINE, EMBASE and Cochrane Central Register of Controlled Trials databases. RCTs and observational studies were included. Data extraction was completed by two authors independently and in duplicate determined the methodological quality of the studies and extracted data.

RESULTS

Of 564 unique citations identified, 16 studies were included: six observational studies and ten RCTs. Four high-quality studies (two observational and two RCTs) were deemed suitable for meta-analysis. Results indicated a statistically significant reduction in the risk of death associated with cinacalcet (hazard ratio: 0.83; 95% credible interval: 0.78-0.89).

CONCLUSION

The results of this meta-analysis indicate that treatment of secondary hyperparathyroidism with calcimimetic therapy may in fact reduce mortality among patients receiving maintenance dialysis. This finding provides justification for a well-designed and adequately powered randomized trial to definitively address the question.

摘要

目的

具有临床结局的随机对照试验(RCT)被视为监管批准的金标准。然而,从设计上来说,它们只能回答少数临床问题。临床决策还需要其他高质量研究。EVOLVE是评估西那卡塞对接受维持性透析的继发性甲状旁腺功能亢进成年患者临床结局影响的最大规模RCT。虽然EVOLVE试验未达到其主要终点,但随机分组时受试者年龄不均衡以及停药率是质疑缺乏死亡率获益的两个原因。我们进行了一项系统文献综述和贝叶斯荟萃分析,将关于口服拟钙剂西那卡塞对临床结局(包括维持性透析患者的全因死亡率、心血管相关死亡率、心血管事件住院、骨折和甲状旁腺切除术)估计影响的随机研究和观察性研究相结合。

方法

数据来源包括MEDLINE、EMBASE和Cochrane对照试验中央注册数据库。纳入RCT和观察性研究。由两名作者独立且重复地完成数据提取,确定研究的方法学质量并提取数据。

结果

在识别出的564条独特引文中,纳入了16项研究:6项观察性研究和10项RCT。四项高质量研究(两项观察性研究和两项RCT)被认为适合进行荟萃分析。结果表明,西那卡塞相关的死亡风险有统计学意义的降低(风险比:0.83;95%可信区间:0.78 - 0.89)。

结论

这项荟萃分析的结果表明,用拟钙剂疗法治疗继发性甲状旁腺功能亢进实际上可能降低接受维持性透析患者的死亡率。这一发现为进行一项设计良好且样本量充足的随机试验以明确解决该问题提供了依据。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验